Cantor Fitzgerald reiterated their buy rating on shares of AnaptysBio (NASDAQ:ANAB) in a research report released on Tuesday, October 16th. They currently have a $140.00 target price on the biotechnology company’s stock.
“. $140 price target. We think positive Dupixent phase 3 nasal polyp data from REGN (Neutral)/SNY (Not Covered) is an incremental positive for ANAB as it helps de-risk ANAB’s readout in this indication in 2H 2019. ANAB is also studying etokimab in chronic sinusitis with nasal polyps (CSwNP) and is guiding for phase 2 data in 2H19 (n=100, placebo controlled study). Because of the similarities in Dupixent and etokimab mechanisms of actions, we believe this should increase the likelihood of etokimab’s success in this study.”,” the firm’s analyst wrote.
ANAB has been the subject of a number of other research reports. Credit Suisse Group set a $147.00 target price on AnaptysBio and gave the stock a buy rating in a report on Thursday, September 27th. Wedbush reaffirmed an outperform rating and set a $138.00 target price on shares of AnaptysBio in a report on Tuesday, September 18th. Zacks Investment Research downgraded AnaptysBio from a buy rating to a hold rating in a report on Tuesday, October 9th. Stifel Nicolaus set a $127.00 target price on AnaptysBio and gave the stock a buy rating in a report on Friday, September 14th. Finally, JMP Securities decreased their price target on AnaptysBio from $180.00 to $153.00 and set a buy rating for the company in a report on Wednesday, August 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $130.50.
ANAB traded down $8.71 on Tuesday, hitting $72.33. The company had a trading volume of 836,519 shares, compared to its average volume of 312,129. AnaptysBio has a 12-month low of $65.93 and a 12-month high of $134.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 16.19 and a quick ratio of 16.19. The firm has a market capitalization of $2.07 billion, a PE ratio of -47.59 and a beta of 3.47.
AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.66) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.05. The business had revenue of $5.00 million for the quarter. As a group, sell-side analysts expect that AnaptysBio will post -2.72 EPS for the current year.
Hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. raised its stake in shares of AnaptysBio by 6.4% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 84,342 shares of the biotechnology company’s stock worth $5,992,000 after buying an additional 5,067 shares during the period. Quantitative Systematic Strategies LLC acquired a new position in shares of AnaptysBio during the 2nd quarter worth approximately $211,000. Brown Advisory Inc. raised its stake in shares of AnaptysBio by 1.5% during the 2nd quarter. Brown Advisory Inc. now owns 102,114 shares of the biotechnology company’s stock worth $7,253,000 after buying an additional 1,500 shares during the period. BlackRock Inc. raised its stake in shares of AnaptysBio by 2.9% during the 2nd quarter. BlackRock Inc. now owns 1,464,624 shares of the biotechnology company’s stock worth $104,046,000 after buying an additional 41,507 shares during the period. Finally, Asymmetry Capital Management L.P. acquired a new position in shares of AnaptysBio during the 2nd quarter worth approximately $2,893,000.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.